EXEL
Exelixis, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
54.87
▲ 1.18 (2.20%)
MARKET · —
Price
Open
54.18
Prev close
53.69
Day high
54.68
Day low
53.70
Volume
1.89M
Market cap
—
P/E (TTM)
—
52W range
33.76 – 57.57
Trailing performance
Returnvs SPY
1W
+5.54%
+6.9%
1M
-2.82%
-6.6%
3M
+8.92%
+5.8%
6M
+23.95%
+12.9%
YTD
+23.39%
+11.1%
1Y
+42.84%
+22.8%
3Y
+153.66%
+79.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
52.41
+4.69% from price
SMA 20
53.74
+0.63% from price
SMA 50
54.24
-0.29% from price
SMA 100
50.85
+7.90% from price
SMA 200
46.90
+15.32% from price
EMA 12
53.28
+2.99% from price
EMA 26
53.65
+2.27% from price
EMA 50
53.25
+3.05% from price
RSI (14)
51.6
Neutral
MACD (12,26,9)
-0.38
Hist 0.10
ATR (14)
1.77
3.27% of price
Realised vol 30D
38.7%
Annualised
Bollinger upper
57.61
20, 2σ
Bollinger lower
49.87
20, 2σ
50 / 200 cross
Golden
54.24 vs 46.90
Trend bias
Above 200
+15.32%
Risk profile
Beta vs SPY
0.61
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
38.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-16.5%
Peak to trough
Max drawdown 5Y
-35.4%
Peak to trough
ATR 14
1.77
3.27% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Exelixis, Valaris, and 3 More Stocks See Action From Activist Investors
Barrons.com · 13h ago
Exelixis (EXEL) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot
Simply Wall St. · 15d ago
Why This Top-Ranked IBD 50 Stock Just Tumbled On Its Earnings
Investor's Business Daily · 16d ago
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 View
Zacks · 16d ago
Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ...
GuruFocus.com · 16d ago
Exelixis Q2 Earnings Call Highlights
MarketBeat · 16d ago
Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.